Better Therapeutics, Inc. (BTTX)
| Market Cap | 5.45K |
| Revenue (ttm) | n/a |
| Net Income | -31.57M |
| EPS | -1.08 |
| Shares Out | 54.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,542 |
| Open | 0.0001 |
| Previous Close | n/a |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.0002 |
| Beta | -40.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 13, 2026 |
About Better Therapeutics
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, incl... [Read more]
News
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Better Therapeutics trading resumes
10:05 EDT Better Therapeutics trading resumes
Better Therapeutics to seek strategic alternatives, be delisted from Nasdaq
Better Therapeutics announced today that the company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the c...
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strateg...
Better Therapeutics trading halted, news pending
09:28 EDT Better Therapeutics trading halted, news pending
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™...
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic disease...
Better Therapeutics enters rebate pact with PBM for AspyreRx diabetes treatment
Better Therapeutics announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers negotiating on behalf of over 70M lives in the US.
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases...
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases...
Better Therapeutics and Glooko team to to integrate AspyreRx to treat T2D
Better Therapeutics and Glooko announced a partnership to integrate Better Therapeutics’ AspyreRx digital behavioral treatment for type 2 diabetes, T2D, into Glooko’s diabetes management platform. Thi...
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic dis...
Better Therapeutics submits breakthrough device application for PDT
Better Therapeutics announced it has submitted a request to the FDA for breakthrough device designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease, or...
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
Better Therapeutics files to sell 20M shares of common stock for holders
17:26 EST Better Therapeutics files to sell 20M shares of common stock for holders
Better Therapeutics strengthens financials with amendment to debt, costs
Better Therapeutics disclosed several initiatives aimed at extending the company’s cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched Asp...
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, t...
Better Therapeutics Earnings Call Transcript: Q3 2023
Better Therapeutics Quarterly report: Q3 2023
Better Therapeutics has published its Q3 2023 quarterly earnings report on November 9, 2023.
Better Therapeutics Earnings release: Q3 2023
Better Therapeutics released its Q3 2023 earnings on November 9, 2023, summarizing the period's financial results.
Better Therapeutics reports Q3 EPS (15c), consensus (21c)
Net loss for the quarter ended September 30, 2023 was $5.9M, compared to $11.4M for the same period in 2022. On a per common share basis, net loss was 15…
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today re...